Loading
Require that approved cancer drugs come with a standard set of data (blood levels, drug interactions, toxicity profile) so anyone can design a safe combination trial without asking the company.
Combination trial designers need pharmacokinetic profiles, metabolic pathways, QT effects, myelosuppression kinetics and immunogenicity data that sit in confidential regulatory dossiers. A standardised, machine-readable 'combination-readiness' annex published at approval would let academics and other companies design combination studies and predict overlapping toxicity without bilateral negotiation.
Shares A standard cross-company combination agreement that takes weeks, not years, to sign, Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Secrecy and intellectual property block collaboration, Too many combinations to test.
Shares DrugBank & ChEMBL, FDA Oncology Approvals (OCE) & Novel Drug Approvals.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares DrugBank & ChEMBL, Secrecy and intellectual property block collaboration.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/